Mind Medicine (mindmed) INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder, meeting primary and key secondary endpoints.
Definium Therapeutics announced positive Phase 3 Emerge study results for DT120 ODT in MDD, substantial cash reserves, and progress across its GAD and MDD clinical programs.
Definium Therapeutics has priced an underwritten public offering of common shares, raising approximately $805 million in gross proceeds.
Definium Therapeutics, Inc. has released an updated corporate presentation on May 19, 2026, detailing its late-stage pipeline for DT120 ODT in GAD and MDD, and DT402 for ASD, alongside its financial position and future milestones.
Definium Therapeutics has dosed the first patient in its Phase 3 Ascend study for DT120 ODT in Major Depressive Disorder, with topline data expected in 2027.
Definium Therapeutics announced significant clinical progress for its DT120 ODT program with three pivotal readouts expected in 2026.
Definium Therapeutics announced its full-year 2025 financial results, highlighting significant progress in its Phase 3 clinical programs and extending its cash runway into 2028.
Definium Therapeutics, Inc. announced the appointment of Roger Adsett to its Board of Directors, expanding the board from six to seven members.
Definium Therapeutics, formerly MindMed, announced a corporate rebrand, a strong cash position of $412 million, and key Phase 3 readouts for its psychiatric drug pipeline in 2026.
MindMed reports Q3 2025 financial results, accelerates its Phase 3 MDD trial, and strengthens its cash position with a recent $242.8 million capital raise.
Mind Medicine (MindMed) Inc. announced the pricing of an underwritten public offering of 18,375,000 common shares at $12.25 per share, expecting gross proceeds of approximately $258.9 million.
MindMed announced preliminary cash, cash equivalents, and investments of $209.1 million as of September 30, 2025, while detailing significant progress in its Phase 3 clinical programs for MM120 in GAD and MDD, and advancing MM402 for ASD.
MindMed announced the publication of positive Phase 2b clinical trial results for MM120 (LSD) in Generalized Anxiety Disorder in the Journal of the American Medical Association, demonstrating significant and sustained symptom improvement.
Mind Medicine (MindMed) Inc. reports continued strong enrollment across its pivotal Phase 3 trials for MM120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder, while announcing Q2 2025 financial results and a new Chief Financial Officer.
Mind Medicine (MindMed) Inc. announced that its shareholders approved the 2025 Equity Incentive Plan, re-elected all six director nominees, and appointed KPMG LLP as auditor at the Annual General and Special Meeting held on June 12, 2025.
Mind Medicine (MindMed) Inc. has announced the appointment of Brandi L. Roberts, a seasoned financial leader with over 25 years of life sciences experience, as its new Chief Financial Officer, effective June 2, 2025.
MindMed reports progress in Phase 3 trials for MM120 in GAD and MDD, appoints a new Chief Commercial Officer, and amends its loan agreement to enhance financial flexibility.
8-K: MindMed Secures $120 Million Loan Facility Amendment to Fuel Clinical and Commercial Activities
MindMed amends its loan agreement for up to $120 million, including a $42 million initial tranche, to refinance existing debt and support ongoing operations.
MindMed has dosed the first patient in its Phase 3 Emerge study, evaluating MM120 ODT for the treatment of Major Depressive Disorder (MDD).
MindMed announces its fourth quarter and full-year 2024 financial results, highlighting significant progress in clinical trials and a strong cash position.
8-K: MindMed Doses First Patient in Phase 3 Panorama Study for MM120 in Generalized Anxiety Disorder
MindMed has announced the first patient dosed in its Phase 3 Panorama study evaluating MM120 ODT for the treatment of generalized anxiety disorder.
MindMed has announced the termination of its Executive President's employment as part of a management restructuring, while also providing an update on its clinical trial programs for MM120 and MM402.
MindMed has dosed the first patient in its Phase 3 Voyage study, evaluating MM120, a novel LSD-based treatment for Generalized Anxiety Disorder (GAD).
MindMed is progressing with Phase 3 trials for its MM120 drug for GAD and MDD, and reports a robust cash balance of $295.3 million.
MindMed has entered into an exchange agreement with existing shareholders, swapping common shares for pre-funded warrants.
MindMed reports a strong cash position and progress in its clinical trials for MM120 in GAD and MDD, along with a new patent extending IP protection.
Mind Medicine (MindMed) Inc. has announced a public offering of common shares and pre-funded warrants, expected to generate approximately $70 million in net proceeds, to advance its research and development programs.
8-K: MindMed Announces $150 Million At-the-Market Equity Program and Terminates Prior Sales Agreement
MindMed has established a new at-the-market equity program to potentially sell up to $150 million in common shares and terminated a previous sales agreement.
8-K: MindMed Achieves Alignment with FDA on Phase 3 Strategy for MM120 in Generalized Anxiety Disorder
MindMed has successfully completed its End-of-Phase 2 meeting with the FDA, securing alignment on the Phase 3 development strategy for MM120 in treating Generalized Anxiety Disorder (GAD).
MindMed's 2024 Annual General and Special Meeting of Shareholders saw the election of six directors, the appointment of KPMG LLP as auditor, and the approval of the 2024 Employee Share Purchase Plan.